If FCR would be the treatment of option, warning has to be taken in individuals with NOTCH1 mutations, in whom rituximab seems to have little additional benefit.fifty nine Other genomic subgroups, for example patients with BIRC3 mutations look to derive very little gain from CIT,111,112 but these effects should be https://saddamz086xgn3.mycoolwiki.com/user